Table of Content



Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Market definition
1.3. Information procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources & third party perspectives
1.3.4. Primary research
1.4. Information analysis
1.4.1. Data analysis models
1.5. Market formulation & data visualization
1.6. Model Details
1.7. Global Market: CAGR Calculation
1.8. Research assumptions
1.9. List of primary and secondary sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.4. Market Summary
Chapter 3. Systemic Scleroderma Treatment Market Variables, Trends & Scope
3.1. Systemic Scleroderma Treatment Market Lineage outlook
3.1.1. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Lack of curative therapies attract new players
3.3.1.2. Growing prevalence of Systemic Scleroderma Treatment
3.3.1.3. Developed regions present major opportunity markets
3.3.1.4. Expanding pharmaceutical pipeline
3.3.2. Market Restraint Analysis
3.3.2.1. Failure of late-stage clinical trial candidates
3.3.2.2. Lack of well-defined regulatory and reimbursement framework impedes growth in developing regions
3.3.2.3. Reimbursement uncertainties in developed regions pose obstacles
3.4. Systemic Scleroderma Treatment Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier Power: Moderate due to the presence of many suppliers
3.4.1.2. Buyer Power: Moderate owing to the presence of providers
3.4.1.3. Substitution Threat: Low owing to no substitutes
3.4.1.4. Threat from new entrant: Moderate due to high buyer switching cost
3.4.1.5. Competitive rivalry: High due to the presence of a large number of generic manufacturers
3.4.2. PESTEL Analysis
3.4.2.1. Political Landscape
3.4.2.2. Environmental Landscape
3.4.2.3. Social Landscape
3.4.2.4. Technology Landscape
3.4.2.5. Legal Landscape
Chapter 4. Systemic Scleroderma Treatment Market: Drug Class Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. Drug Class market share analysis, 2019 & 2027
4.3. Drug Class Dashboard
4.4. Global Systemic Scleroderma Treatment Market, by Drug Class, 2016 to 2027
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following:
4.5.1. Immunosuppressors
4.5.1.1. Immunosuppressors Market, 2016 - 2027 (USD Million)
4.5.2. Phosphodiesterase 5 inhibitors - PHA
4.5.2.1. Phosphodiesterase 5 inhibitors - PHA Market, 2016 - 2027 (USD Million)
4.5.3. Endothelin Receptor Antagonists
4.5.3.1. Endothelin Receptor Antagonists Market, 2016 - 2027 (USD Million)
4.5.4. Prostacyclin Analogues
4.5.4.1. Prostacyclin Analogues Market, 2016 - 2027 (USD Million)
4.5.5. Calcium Channel Blockers
4.5.5.1. Calcium Channel Blockers Market, 2016 - 2027 (USD Million)
4.5.6. Others
4.5.6.1. Others Market, 2016 - 2027 (USD Million)
Chapter 5. Systemic Scleroderma Treatment Market: Regional Estimates & Trend analysis, by Drug Class, and Indication
5.1. Regional Market Snapshot
5.2. Regional Market Share and Leading Players, 2019
5.2.1. North America
5.2.2. Europe
5.2.3. Asia Pacific
5.2.4. Latin America
5.2.5. Middle East & Africa
5.3. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Latin America
5.3.5. Middle East & Africa
5.4. Market Size & Forecasts and Trend Analysis, 2019 to 2027:
5.4.1. North America
5.4.1.1. North America Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.1.2. U.S.
5.4.1.2.1. U.S. Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.1.3. Canada
5.4.1.3.1. Canada Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2. Europe
5.4.2.1. Europe Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.2. U.K.
5.4.2.2.1. U.K. Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.3. Germany
5.4.2.3.1. Germany Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.4. Spain
5.4.2.4.1. Spain Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.5. France
5.4.2.5.1. France Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.2.6. Italy
5.4.2.6.1. Italy Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3. Asia Pacific
5.4.3.1. Asia Pacific Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.2. China
5.4.3.2.1. China Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.3. Japan
5.4.3.3.1. Japan Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.4. India
5.4.3.4.1. India Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.3.5. Australia
5.4.3.5.1. Australia Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4. Latin America
5.4.4.1. Latin America Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4.2. Brazil
5.4.4.2.1. Brazil Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4.3. Mexico
5.4.4.3.1. Mexico Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.4.4. Argentina
5.4.4.4.1. Argentina Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5. Middle East Africa
5.4.5.1. MEA Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5.2. South Africa
5.4.5.2.1. South Africa Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5.3. Saudi Arabia
5.4.5.3.1. Saudi Arabia Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
5.4.5.4. UAE
5.4.5.4.1. UAE Systemic Scleroderma Treatment Market, 2016 - 2027 (USD Million)
Chapter 6. Company Profiles
6.1. Recent developments & impact analysis, by key market participants
6.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
6.3. Public Companies
6.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
6.3.2. Competitive Dashboard Analysis
6.3.3. Market Differentiators
6.4. Private Companies
6.4.1. Regional network map
6.5. Company Profiles
6.5.1. Johnson & Johnson Services, Inc.
6.5.1.1. Company Overview
6.5.1.2. Financial Performance
6.5.1.3. Product Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Boehringer Ingelheim International GmbH
6.5.2.1. Company Overview
6.5.2.2. Financial Performance
6.5.2.3. Product Benchmarking
6.5.2.4. Strategic Initiatives
6.5.3. F. Hoffman La Roche Ltd.
6.5.3.1. Company Overview
6.5.3.2. Financial Performance
6.5.3.3. Product Benchmarking
6.5.3.4. Strategic Initiatives
6.5.4. United Therapeutics Corporation
6.5.4.1. Company Overview
6.5.4.2. Financial Performance
6.5.4.3. Product Benchmarking
6.5.4.4. Strategic Initiatives
6.5.5. Novartis AG
6.5.5.1. Company Overview
6.5.5.2. Financial Performance
6.5.5.3. Product Benchmarking
6.5.5.4. Strategic Initiatives
6.5.6. GlaxoSmithKline plc. (GSK)
6.5.6.1. Company Overview
6.5.6.2. Financial Performance
6.5.6.3. Product Benchmarking
6.5.6.4. Strategic Initiatives
6.5.7. Teva Pharmaceutical Industries Ltd.
6.5.7.1. Company Overview
6.5.7.2. Financial Performance
6.5.7.3. Product Benchmarking
6.5.7.4. Strategic Initiatives
6.5.8. Gilead Sciences Inc.
6.5.8.1. Company Overview
6.5.8.2. Financial Performance
6.5.8.3. Product Benchmarking
6.5.8.4. Strategic Initiatives
6.5.9. Pfizer Inc.
6.5.9.1. Company Overview
6.5.9.2. Financial Performance
6.5.9.3. Product Benchmarking
6.5.9.4. Strategic Initiatives
6.5.10. Mylan N.V.
6.5.10.1. Company Overview
6.5.10.2. Financial Performance
6.5.10.3. Product Benchmarking
6.5.10.4. Strategic Initiatives



List of Tables



TABLE 1 List Of Abbreviation
TABLE 2 North America Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 3 U.S. Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 4 Canada Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 5 Europe Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 6 U.K. Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 7 Germany Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 8 Italy Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 9 France Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 10 Spain Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 11 Asia Pacific Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 12 Japan Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 13 China Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 14 India Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 15 Australia Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 16 Latin America Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 17 Brazil Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 18 Mexico Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 19 Argentina Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 20 MEA Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 21 South Africa Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 22 Saudi Arabia Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)
TABLE 23 UAE Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2027 (USD Million)